邵楠 李小彥 肖明兵 江楓 倪溫慨 陸翠華 倪潤洲
·論著·
納米磁珠分選聯(lián)合TRFIA檢測血清半乳糖凝集素-3對胰腺癌診斷的價(jià)值
邵楠 李小彥 肖明兵 江楓 倪溫慨 陸翠華 倪潤洲
目的采用納米磁珠分選聯(lián)合時(shí)間分解熒光免疫測定(納米磁珠-TRFIA)的方法檢測血清半乳糖凝集素-3(Galectin-3)的濃度,評價(jià)其對胰腺癌的診斷價(jià)值。方法收集88例胰腺癌、50例急性胰腺炎、10例胰腺囊腫患者的血清,以20位健康者作為正常對照組。先采用Galectin-3抗體耦聯(lián)的納米磁珠對人外周血清進(jìn)行分選,再用TRFIA法檢測Galectin-3濃度,并與常規(guī)TRFIA法檢測所得的血清Galectin-3濃度進(jìn)行比較。應(yīng)用受試者工作特征(ROC)曲線下面積(AUC)確定診斷胰腺癌的界值,獲取診斷胰腺癌的敏感性。結(jié)果納米磁珠-TRFIA法檢測Galectin-3濃度在0.78~100 ng/ml范圍內(nèi)呈線性關(guān)系,批內(nèi)CV≤6.38%,批間CV≤7.22%,平均回收率為105.3%。納米磁珠-TRFIA法檢測正常對照組的血清Galectin-3濃度為0.38(0.02~3.06)ng/ml,顯著高于常規(guī)TRFIA法檢測得到的0.18(0.00~2.64)ng/ml(P=0.000)。納米磁珠-TRFIA法檢測的胰腺癌、急性胰腺炎、胰腺囊腫患者血清Galectin-3濃度分別為4.85(0.00~42.67) 、0.69(0.00~13.62)、0.70(0.00~14.54)ng/ml,胰腺癌患者明顯高于急性胰腺炎、胰腺囊腫患者及正常對照者(P值均<0.01),而其他3組之間的濃度差異無統(tǒng)計(jì)學(xué)意義。Galectin-3診斷胰腺癌的AUC為0.851±0.040,95%可信區(qū)間0.772~0.929。以Galectin-3濃度1.07 ng/ml為診斷界值時(shí),胰腺癌、急性胰腺炎、胰腺囊腫患者及正常對照者的陽性率分別為84.1%(74/88)、34.0%(17/50)、20.0%(2/10)、10.0%(2/20),對胰腺癌的診斷敏感性顯著高于其他3組(P值均<0.01)。結(jié)論納米磁珠分選聯(lián)合TRFIA法可富集血清中的Galectin-3,從而提高血清Galectin-3檢出敏感性及其對胰腺癌的診斷價(jià)值。
胰腺腫瘤; 時(shí)間分解熒光免疫測定; 半乳糖凝集素-3; 納米磁珠分選
采用血清標(biāo)志物來提高胰腺癌的早期診斷水平是最易推廣應(yīng)用的方法,但目前臨床常用的標(biāo)志物診斷特異性及敏感性較低。半乳糖血凝素-3(Galectin-3)是半乳凝素家族的一員,具有識別糖蛋白和糖脂的特異性低聚糖結(jié)構(gòu)。以往的研究結(jié)果顯示[1-4],胰腺癌組織Galectin-3蛋白表達(dá)上調(diào),胰腺癌患者外周血Galectin-3濃度也異常升高,提示其對胰腺癌具有診斷價(jià)值[3-4]。但常用的檢測Galectin-3的方法,如ELISA或化學(xué)發(fā)光法等的檢測靈敏度有限,且需消耗較多血清。本研究自行建立納米磁珠分選聯(lián)合時(shí)間分解熒光免疫(Time resolved fluoroimmunoassay,TRFIA)的方法(納米磁珠-TRFIA法)檢測血清Galectin-3,具有較好的靈敏度及穩(wěn)定性,現(xiàn)報(bào)道如下。
一、研究對象
收集南通大學(xué)附屬醫(yī)院2010年5月至2012年12月間住院的胰腺癌患者88例,男性49例,女性39例,中位年齡57歲;胰腺囊腫患者10例,男性5例,女性5例,中位年齡50歲;急性胰腺炎患者50例,男性27例,女性23例,中位年齡52歲。所有病例均經(jīng)臨床和(或)病理學(xué)證實(shí)。以20例體檢健康者作為正常對照,男性11例,女性9例,中位年齡51歲。所有患者均在治療前采集清晨空腹靜脈血,分離血清后置-80℃冰箱保存。
二、納米磁珠-TRFIA檢測方法
采用GoldMag?-CS納米金磁微粒(30 nm)蛋白耦聯(lián)試劑盒(西安金磁納米生物科技有限公司)將經(jīng)2次耦聯(lián)液預(yù)處理的GoldMag?-CS納米金磁微粒與耦聯(lián)的抗人Galectin-3單抗(R&D公司)置37℃、180 r/min振蕩耦聯(lián)20 min,封閉液封閉后加入待測血清或Galectin-3標(biāo)準(zhǔn)蛋白置37℃反應(yīng)1 h,磁性分離2 min,吸出的血清可檢測其他指標(biāo)。分離后的磁珠經(jīng)洗滌后加入生物素標(biāo)記的抗人Galectin-3 抗體(R&D公司)置37℃孵育1 h,磁性分離后棄上清,洗滌后加入Eu3+標(biāo)記的streptavidin (PE公司)37℃避光孵育1 h。磁性分離,洗滌,加入增強(qiáng)液反應(yīng)后移至96孔檢測板,置PE公司VICTOR X5時(shí)間分解免疫熒光器以激發(fā)波長337 nm、發(fā)射波長615 nm測各孔熒光值。 根據(jù)標(biāo)準(zhǔn)曲線計(jì)算樣本Galectin-3濃度。應(yīng)用受試者工作特征(ROC)曲線下面積(AUC)確定診斷胰腺癌的界值,獲取診斷胰腺癌的敏感性。
三、常規(guī)TRFIA檢測方法
參照肖明兵等[4]之前報(bào)道的TRFIA法。
四、統(tǒng)計(jì)學(xué)處理
用Stata 8.0及SPSS 15.0統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)分析。應(yīng)用納米磁珠-TRFIA法及常規(guī)TRFIA法檢測的正常血清Galectin-3濃度之間的比較采用配對t檢驗(yàn)。因納米磁珠-TRFIA法檢測血清Galectin-3在各組中結(jié)果呈偏態(tài)分布,故以中位數(shù)(范圍)表示,各組間的差異比較采用秩和檢驗(yàn)。計(jì)數(shù)資料以百分率表示,率的比較采用χ2檢驗(yàn),當(dāng)理論頻數(shù)小于5時(shí),采用Fisher′s確切概率法。P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
一、納米磁珠-TRFIA檢測Galectin-3方法的建立
30 nm粒徑的超順磁性復(fù)合微粒,其核為納米磁性粒子,核表面是金的殼層,不需共價(jià)耦聯(lián)試劑可成功將Galectin-3抗體耦聯(lián)在納米金磁微粒表面,耦聯(lián)有Galectin-3抗體的納米金磁微??梢詮难逯形匠鯣alectin-3,分離后的血清可以進(jìn)一步加入第二種抗體耦聯(lián)磁珠以進(jìn)行另一個(gè)標(biāo)志物的檢測,充分提高了血清樣本利用率。該法檢測系列稀釋的Galectin-3標(biāo)準(zhǔn)蛋白,在0.78~100 ng/ml范圍內(nèi)呈線性關(guān)系(圖1)。批內(nèi)CV≤6.38%,批間CV≤7.22%,平均回收率為105.3%。
圖1納米磁珠-TRFIA法檢測Galectin-3的劑量-反應(yīng)曲線
二、納米磁珠-TRFIA法及常規(guī)TRFIA法檢測正常對照組血清Galectin-3濃度的比較
納米磁珠-TRFIA法檢測20例健康者血Galectin-3濃度為0.38(0.02~3.06)ng/ml,常規(guī)TRFIA法檢測的濃度為0.18(0.00~2.64)ng/ml(圖2),納米磁珠-TRFIA法的檢測值顯著高于常規(guī)TRFIA法,差異有統(tǒng)計(jì)學(xué)意義(t=5.2268,P=0.000)。
三、各組患者血清Galectin-3濃度及其對胰腺癌的診斷價(jià)值
納米磁珠-TRFIA法檢測的胰腺癌、急性胰腺炎、胰腺囊腫患者及正常對照者血清Galectin-3濃度分別為4.85(0.00~42.67)、0.69(0.00~13.62)、0.70(0.00~14.54)、0.38(0.02~3.06)ng/ml(圖3a)。胰腺癌患者血清Galectin-3濃度明顯高于急性胰腺炎、胰腺囊腫患者及健康者(Z值分別為5.236、3.210、5.766,P值分別為0.0013、0.0000、0.0000),而急性胰腺炎、胰腺囊腫患者及健康者之間的血清Galectin-3濃度差異無統(tǒng)計(jì)學(xué)意義(P值均>0.05)。
Galectin-3診斷胰腺癌的AUC為0.851±0.040,95%可信區(qū)間0.772~0.929(圖3b)。以Galectin-3濃度1.07 ng/ml為診斷界值時(shí),胰腺癌、急性胰腺炎、胰腺囊腫患者及健康者的陽性率分別為84.1%(74/88)、34.0%(17/50)、20.0%(2/10)、10.0%(2/20),對胰腺癌的診斷敏感性顯著高于其他3組(χ2=35.6231,P=0.000)。
圖2納米磁珠-TRFIA法及常規(guī)TRFIA法檢測的20例健康者血清Galectin-3濃度的比較
圖3各組血清Galectin-3濃度散點(diǎn)圖(a)及Galectin-3診斷胰腺癌的ROC曲線(b)
Galectin-3在結(jié)直腸癌、胃癌、肝癌、甲狀腺癌、垂體腺瘤、腎透明細(xì)胞癌、浸潤性乳腺癌、舌鱗狀細(xì)胞癌、惡性嗜鉻細(xì)胞瘤、上皮性卵巢癌、膀胱癌等多種腫瘤中高表達(dá)[5-13],其表達(dá)的增加與腫瘤的轉(zhuǎn)移和疾病進(jìn)展呈正相關(guān)。本研究組首次報(bào)道Galectin-3在胰腺癌組織高表達(dá),同時(shí)其患者血清中Galectin-3濃度顯著升高,可與CA19-9聯(lián)合診斷胰腺癌[3-4]。
本研究組以往應(yīng)用TRFIA法檢測血清Galectin濃度,是取代放射性免疫分析的一種定量檢測方法[14]。它的基本原理是利用3價(jià)稀土離子(如Eu3+、Sm3+、Dy3+、Tb3+)作為示蹤物,延遲檢測壽命較長的特異性激發(fā)熒光以排除非特異性及背景熒光的干擾,即測定復(fù)合物中的稀土離子被激發(fā)的延遲熒光強(qiáng)度,從而確定待測蛋白的濃度。它具有靈敏性高、特異性強(qiáng)、穩(wěn)定性好的特點(diǎn)。
本研究采用納米磁珠-TRFIA法檢測血清Galectin-3濃度。納米磁珠兼具高分子粒子和磁性粒子的特性,具有固定效率高、機(jī)械強(qiáng)度高,耐腐蝕、易于磁性分離及生物相容性好的特點(diǎn),為極具應(yīng)用價(jià)值的新型功能材料。在生物醫(yī)藥領(lǐng)域,納米磁珠可應(yīng)用于蛋白質(zhì)、DNA、細(xì)菌及病毒的檢測,并大大簡化實(shí)驗(yàn)流程、縮短測試周期、明顯提高檢測靈敏度[15]。本研究先采用抗體耦聯(lián)的納米磁珠進(jìn)行分選,從體積較大的標(biāo)本中富集篩選出目的蛋白,使得樣本得到一次濃縮,從而大大提高了檢測靈敏度。本研究顯示,正常對照組血清Galectin-3濃度高于用常規(guī)TRFIA法檢測的同1份標(biāo)本的濃度,且對胰腺癌的診斷敏感性從常規(guī)TRFIA法的70%提高到84.1%,證實(shí)納米磁珠-TRFIA法優(yōu)于常規(guī)TRFIA法。而且該法的平均回收率高,批內(nèi)、批間差異在6%~7%,具有較好穩(wěn)定性及重復(fù)性。此外,該法可以用耦聯(lián)不同抗體的納米磁珠先后進(jìn)行富集,使患者血清得以重復(fù)利用,從而達(dá)到高通量檢測的目的。因此,應(yīng)用納米磁珠-TRFIA法檢測血清Galectin-3值得在臨床推廣,其對胰腺癌的診斷價(jià)值則需更多的臨床病例驗(yàn)證。
[1] Chen JH, Ni RZ, Xiao MB, et al. Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int, 2009,8:193-200.
[2] Xie L, Ni WK, Chen XD, et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol, 2012, 138:1035-1043.
[3] 葛飛, 倪潤洲, 肖明兵, 等. 血清Galectin-3對胰腺癌診斷價(jià)值的初探. 南通大學(xué)學(xué)報(bào)(醫(yī)學(xué)級版), 2010,30:32-34.
[4] 肖明兵, 謝玲, 倪溫慨, 等. 血清半乳糖凝集素3對胰腺癌的診斷價(jià)值. 中華胰腺病雜志, 2012,12:75-78.
[5] Zaia Povegliano L, Oshima CT, de Oliveira Lima F, et al. Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J Gastrointest Cancer, 2011,42:217-221.
[6] Matsuda Y, Yamagiwa Y, Fukushima K, et al. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res,2008,38:1098-111.
[7] Righi A, Jin L, Zhang S, et al. Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol,2010,326:8-14.
[8] Sakaki M, Fukumori T, Fukawa T, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest,2010,57:152-157.
[9] Koo JS, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J,2011,52:89-97.
[10] Alves PM, Godoy GP, Gomes DQ, et al. Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract,2011,207:236-240.
[11] Kim MK, Sung CO, Do IG, et al. Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol,2011,16:352-358.
[12] Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol,2010,31:277-285.
[13] Saffar H, Sanii S, Heshmat R, et al. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma. Am J Clin Pathol,2011,135:454-460.
[14] Kupstat A, Kumke MU, Hildebrandt N. Toward sensitive, quantitative point-of-care testing (POCT) of protein markers: miniaturization of a homogeneous time-resolved fluoro-immunoassay for prostate-specific antigen detection. Analyst,2010,136:1029-1035.
[15] 趙子愷, 惠國華, 陳裕泉. 納米磁珠材料的制備及在生物醫(yī)學(xué)領(lǐng)域的應(yīng)用進(jìn)展. 國際生物醫(yī)學(xué)工程雜志,2009,32:183-189.
Thevalueofserumgalectin3detectedbynanomagneticbeadssortingtimeresolvedfluoroimmunoassaytandemanalysisinthediagnosisofpancreaticcancer
SHAONan,LIXiao-yan,XIAOMing-bing,JIANGFeng,NIWen-kai,LUCui-hua,NIRun-zhou.
DepartmentofGastroenterology,AffiliatedHospital,NantongUniversity,Nantong226001,China
NIRong-zhou,Email:nirz@163.com
ObjectiveTo study the value of serum galectin-3 detected by nanomagnetic beads sorting time resolved fluoroimmunoassay (TRFIA) tandem analysis in the diagnosis of pancreatic cancer.MethodsThe serum of 88 cases of pancreatic cancer, 50 cases of acute pancreatitis, 10 cases of pancreatic cysts, and 20 cases of healthy volunteers as control were collected. First, galectin-3 antibody coupled nanomagnetic-beads was used to sort the serum, then TRFIA was applied to detect the level of galectin 3, and the result was compared with that of routine TRFIA. ROC curve was constructed to determine the cutoff value and sensitivity for pancreatic cancer diagnosis.ResultsThe method of nanomagnetic beads sorting TRFIA detected the level of galectin 3 between 0.78 and 100 ng/ml in a linear manner, the intra-CV was ≤6.38%, and inter-CV was ≤7.22%, and average recovery rate was 105.3%. The serum level of galectin-3 in control group by nanomagnetic beads sorting TRFIA was 0.38(0.02~3.06)ng/ml, which was significantly higher than that detected by routine TRFIA [0.18(0.00~2.64)ng/ml,P=0.000). The serum levels of galectin-3 by nanomagnetic beads sorting TRFIA in pancreatic cancer, acute pancreatitis, pancreatic cysts and healthy volunteers were 4.85(0.00~42.67), 0.69(0.00~13.62), 0.70(0.00~14.54), 0.38(0.02~3.06)ng/ml, and the level of galectin-3 in pancreatic cancer was significantly higher than that in acute pancreatitis, pancreatic cysts and healthy volunteers group (P<0.01), while the difference among the other three group was not significantly different. The AUC of galectin-3 for pancreatic cancer was 0.851±0.040, 95%CI: 0.772~0.929. While using 1.07 ng/ml as the cut-off value, the positive rates for the diagnosis of pancreatic cancer, acute pancreatitis, pancreatic cysts and healthy volunteers were 84.1%(74/88), 34.0%(17/50), 20.0%(2/10), 10.0%(2/20), and the sensitivity for diagnosis of pancreatic cancer was significantly higher than those in other 3 groups (P<0.01).ConclusionsNanomagnetic beads sorting TRFIA tandem analysis method can enrich serum galectin-3, and increase the sensitivity of detection for pancreatic cancer and enhance the diagnostic value of galectin-3 for pancreatic cancer.
Pancreatic neoplasms; Time resolved fluoroimmunoassay; Galectin-3; Nanomagnetic beads sorting
10.3760/cma.j.issn.1674-1935.2013.05.004
江蘇省“六大人才高峰”資助項(xiàng)目(WSN-065);江蘇省衛(wèi)生廳資助項(xiàng)目(H200923);南通市科技計(jì)劃資助項(xiàng)目(S2010012、HS2011004)
226001 南通,南通大學(xué)附屬醫(yī)院消化內(nèi)科
倪潤洲, Email:nirz@163.com
2013-05-28)
(本文編輯:呂芳萍)